ライフサイエンスコーパス: effector T-cell

1 d abundance of neutrophils, macrophages, and effector T cells.

2 ty and survival of existing antigen-specific effector T cells.

3 .031) and allergen-driven T(H)2 cytokines by effector T cells.

4 erentiation of IFN-gamma and IL-21-producing effector T cells.

5 an increased frequency of cytokine-producing effector T cells.

6 Foxp3(+) regulatory T cells to IFN-gamma(+) effector T cells.

7 ction, decreasing the number of intratumoral effector T cells.

8 at affect the balance between regulatory and effector T cells.

9 sentation module, promoted the generation of effector T cells.

10 vity and hapten-specific IFN-gamma-producing effector T cells.

11 by a process that seems to be driven by CD8 effector T cells.

12 ent conjugate formation in primary naive and effector T cells.

13 promoted bacterial persistence by inhibiting effector T cells.

14 ent with their co-localization with T-bet(+) effector T cells.

15 or signaling and regulating the migration of effector T cells.

16 cells arise from a subset of fate-permissive effector T cells.

17 in adult mice restricted to rapidly dividing effector T cells.

18 epigenetic silencing of pro-memory genes in effector T cells.

19 inhibitors of T-bet function in CD4 and CD8 effector T cells.

20 ding IL-13(+)IL-17(+)CD4(+) double-producing effector T cells.

21 apoptosis and inhibiting expansion of donor effector T cells.

22 on and suppresses metabolic reprogramming of effector T cells.

23 antigen, despite increased numbers of CD8(+) effector T cells.

24 inducing regulatory T cells, and inhibiting effector T cells.

25 nction through CD39/CD73 pathway to regulate effector T cells.

26 d-brain barrier and a large influx of CD8(+) effector T cells.

27 eg frequency and by an increase in activated effector T cells.

28 , imparting transient protection against the effector T cells.

29 elates with RICD sensitivity in human CD8(+) effector T cells.

30 on of autologous and allogenic CD4(+)CD25(-) effector T cells.

31 and differentiate into highly proliferative effector T cells.

32 he generation of short-lived tissue-invasive effector T cells.

33 which transforms them into rapidly dividing effector T cells.

34 h its impact on both regulatory T (Treg) and effector T cells.

35 fector T cell apoptosis or uptake of GZMB by effector T cells.

36 activation, and dermal infiltration by T(h)1 effector T cells.

37 immune response mediated by graft-attacking effector T cells.

38 leading to imbalanced cytokine production by effector T cells.

39 are transcriptionally distinct from classic effector T cells.

40 ulation of pathogenic IL5(+) IL17A(+) CD4(+) effector T-cells.

41 f CD8(+) central memory T cells and terminal effector T cells, a decrease in the coexpression of inhi

42 Our data show that early effector T cells accumulated in the skin during the acut

43 genetic deletion of Fcgr2b increased CD8(+) effector T cell accumulation, resulting in accelerated g

44 y rates, driven by T cell signaling, promote effector T cell activation and expansion and Treg dysfun

45 y during bacterial infections by controlling effector T cell activation.

46 erity and to delay disease onset by blocking effector T cell activation.

47 force at the forefront of pathogen-specific effector T cell activities and establish novel practical

48 that systemic activation of NRF2 suppresses effector T cell activities independently of Tregs and th

49 Human Tr1 cells suppress proliferation of effector T cells (adaptive immune response) and producti

50 hil activation, recruitment and injury, with effector T cells also involved.

51 ng showed enhanced infiltration of antitumor effector T cells and a skewed immunogenic immune profile

52 2 and 3 are antagonists of T-bet function in effector T cells and are important for the control of in

53 xp3(+) T cells, whereas high levels expanded effector T cells and caused severe autoimmunity.

54 creased occurrence of regulatory T cells and effector T cells and decreased natural killer (NK) cells

55 le of intestinal Tr1 cells in the control of effector T cells and development of diabetes.

56 ut not knockdown alone, increased numbers of effector T cells and eliminated the virus.

57 ocyte subpopulation essential for curtailing effector T cells and establishing peripheral tolerance.

58 fatty-acid synthesis favors Treg cells over effector T cells and how this imbalance can be overcome.

59 hat OPC differentiation is inhibited by both effector T cells and IFNgamma overexpression by astrocyt

60 ion, both in donor-derived CD4(+) and CD8(+) effector T cells and in Foxp3(+) regulatory T cells.

61 ls that an oncolytic vaccinia virus attracts effector T cells and induces PD-L1 expression on both ca

62 ne C3ar1/C5ar1 signaling causes expansion of effector T cells and instability of regulatory T cells a

63 , Id3 controls the differentiation of CD8(+) effector T cells and is essential for T(R) cell maintena

64 dispensable for generating cytotoxic CD8(+) effector T cells and maintaining memory CD8(+) T cell po

65 ating lymphopenia and a higher percentage of effector T cells and natural killer (NK) cells present i

66 nse, including inhibition of the activity of effector T cells and of antigen presenting cells via upr

67 C1s, expands the pool of tumour-infiltrating effector T cells and reduces tumour burden.

68 The involvement of effector T cells and regulatory T (T reg) cells in oppos

69 P2X7 stimulation affected cell cycling of effector T cells and resulted in generation of mitochond

70 Cells catabolizing Trp and Arg suppress effector T cells and stabilize regulatory T cells to sup

71 semination and host morbidity by controlling effector T cells and the associated downstream hyperacti

72 (T(reg)) cells that restrict the function of effector T cells and thereby promote tumour growth(1).

73 aled minimal overlap in TCR sequence between effector T cells and Tregs in the CNS.

74 ponses and after vaccination by synergy with effector T cells and virus-specific antibodies.

75 burden and splenomegaly, along with distinct effector T-cell and monocyte profiles.

76 vascular inflammation, enriched for PD-1(+) effector T cells, and amplified tissue production of mul

77 e IL-2 receptor alpha chain, CD45RO(+)CD4(+) effector T cells, and autoantibodies, and this was predi

78 expression profiles characteristic of CD8(+) effector T cells, and chromatin regions uniquely accessi

79 ncreased inflammatory macrophages and CD8(+) effector T cells, and loss of glucose tolerance under st

80 timuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.

81 t but was not associated with an increase in effector T cell apoptosis or uptake of GZMB by effector

82 Ab) that bridge tumor cells and CD3-positive effector T cells are being developed against many tumor

83 Whereas effector T cells are found in the brain parenchyma where

84 vel, how it impacts cytokine production when effector T cells are restimulated is unknown.

85 during M. tuberculosis infection, activated effector T cells are the major source accounting for IL-

86 anti-TIM-3 treatment promotes generation of effector T cells as shown by acquisition of an activated

87 lii-induced exhaustion shows upregulation of effector T cell-associated genes in the absence of NFAT1

88 f circulating gluten-specific Treg cells and effector T cells both increased significantly after oral

89 onged approaches is to expand tumor-specific effector T-cells, break checkpoint receptor-mediated tol

90 TY 720, which depletes circulating naive and effector T cells but not tissue-restricted T cells, we s

91 itive Treg cells suppressed proliferation of effector T cells, but only Tr1 cells suppressed secretio

92 dies that redirect the cytotoxic activity of effector T cells by binding to CD3, the signaling compon

93 type 2 and type 17 helper (T(H)2 and T(H)17) effector T cells by Wnt and Hippo pathway-dependent mech

94 tion of regulatory T cells (Treg) and dampen effector T cells can be effective to limit stromal kerat

95 The anti-tumour activity of effector T cells can be therapeutically unleashed, and i

96 Activated donor effector T cells can differentiate into pathogenic T hel

97 The ratio between T reg and effector T cells can therefore determine the outcome of

98 While UC-associated CD8(+) effector T cells can trigger tissue destruction and prod

99 ion can cause Tregs to de-differentiate into effector T cells capable of producing proinflammatory cy

100 s exhibited the phenotype characteristics of effector T cells (CD45RA(+), CD45RO-/lo, CD62L(-), CD27l

101 of chemokines involved in the recruitment of effector T cells compared to WT.

102 5), as demonstrated by increased NK cell and effector T-cell cytolytic function, reduced T-cell PD-1

103 t, the actual range, regulation, and role of effector T cell-derived chemokines remains incompletely

104 Arteries infiltrated by PD-1(+) effector T cells developed microvascular neoangiogenesis

105 iate metabolic pathways can alter or prevent effector T cell differentiation and function.

106 Overexpression of NR4A1 inhibits effector T cell differentiation, whereas deletion of NR4

107 and reshaping of cell proteomes that permits effector T cell differentiation.

108 le or repeated exposure to antigen, delaying effector T-cell differentiation and exhaustion.

109 V tet(low) and tet(high) CTLs are functional effector T cells differing by proliferation, numbers in

110 Notably, CD38(+)Ki67(+)CD8(+) effector T cells directed against novel epitopes were re

111 upled to production of differentiated CD4(+) effector T cells during clonal selection.

112 joint inflammation ensues as tissue-invasive effector T cells emerge and protective joint-resident ma

113 Effector T cells equipped with engineered antigen recept

114 frequency of T helper type 1 (Th1)-like CD4 effector T cells even though anti-PD-1 monotherapy is no

115 D) regulates immune responses by restraining effector T cell expansion and limiting nonspecific damag

116 egative regulatory programs, which constrain effector T cell expansion and prevent increasing oligocl

117 by rapamycin treatment during secondary CD8 effector T cell expansion, and is dependent on the signa

118 ert into virtual memory cells without clonal effector T cell expansion.

119 rotection include skewing of regulatory over effector T cells, expansion of regulatory T-cell subsets

120 Rag2(-/-) mice receiving NLRX1(-/-) naive or effector T cells experienced increased disease activity

121 differentiation of naive CD8(+) T cells into effector T cells expressing high levels of T-box transcr

122 8(+) T cells, there is an increase of CD8(+) effector T cells expressing the stimulatory receptor Klr

123 on-induced loss of lymphocytes and increased effector T cell fitness in nutrient-limiting conditions,

124 eoplasms, antigen-presenting cells (APC) and effector T cells form transcellular molecular complexes.

125 tionality as controls but may require higher effector T-cell frequencies to ensure pathogen control.

126 n be established by "pulling" virus-specific effector T cells from circulation to the genital mucosa

127 become immune resistant through exclusion of effector T cells from the tumor microenvironment is not

128 to type I interferons, which interfered with effector T cell function and increased the expression of

129 latory pathways play key roles in regulating effector T cell function and responses to anti-PD-L1/PD-

130 rives specialized gene programs that dictate effector T cell function at sites of infection.

131 kin 6 (IL-6) from epithelial cells, tailored effector T cell function, promoting increases in gingiva

132 l expansion, T regulatory cell depletion, or effector T cell function.

133 e expression of T-bet, a master regulator of effector T cell function.

134 12-TIGIT) are critical to the acquisition of effector T-cell function and ensuing secretion of pathog

135 We previously reported that donor effector T-cell function and graft-versus-host disease (

136 evidence that altered myelopoiesis, reduced effector T-cell function, and expansion of immature myel

137 ased effector T-cell infiltration, increased effector T-cell function, and increased memory T cells i

138 t can be therapeutically targeted to restore effector T-cell function.

139 Effector T cells have the capability of recognizing and

140 , Th9 and Th17 cells are conventional CD4(+) effector T cells identified as secretors of prototypical

141 sease phenotypes are not driven by miR-27 in effector T cells in a cell-autonomous manner.

142 However, the pathogenic function of CD4(+) effector T cells in AIH is not fully understood.

143 fection, reduced frequencies of SIV-specific effector T cells in an extralymphoid tissue site were al

144 ses in systemic viral infections and retards effector T cells in autoimmune diabetes.

145 vivo in humanized mouse models, and altered effector T cells in colon explants from UC patients grow

146 an serve as APCs for local allergen-specific effector T cells in patients with allergic LPRs.

147 nimmune" modality for intratumoral T reg and effector T cells in promoting tumor growth through the p

148 at the donor MDSCs administration suppressed effector T cells in recipients.

149 is was associated with an increase in BM CD8 effector T cells in RIC mice and elevated blood and BM p

150 (ICOSL) blockade led to a local expansion of effector T cells in the brain without affecting IL-10 pr

151 ls (Tregs) and reduction of encephalitogenic effector T cells in the central nervous system.

152 here is an elevated prevalence of pathogenic effector T cells in the glands with a sexually dimorphic

153 B, TRAF1, and mTOR in the persistence of CD8 effector T cells in the lung parenchyma, thereby allowin

154 Treg cells lost their ability to suppress effector T cells in the presence of IL-33.

155 This resulted in increased numbers of effector T cells in the tumor, and T cell depletion abol

156 Ectopic expression of TOX in effector T cells in vitro induced a transcriptional prog

157 ted IFN-gamma reporter mice show that CD4(+) effector T cells including follicular helper T (Tfh) cel

158 Naive CD8(+) T cells differentiating into effector T cells increase glucose uptake and shift from

159 flammation (asthma promotion) or suppressing effector T cells (increased susceptibility to respirator

160 d 3 different features: increased numbers of effector T cells; increased expression of genes that sup

161 ethylating drug increases tumor-infiltrating effector T cells, increases a subset of M2 macrophages,

162 SCFA also suppressed effector T cell induction in the CLN and mesenteric lymp

163 gents, which were characterized by increased effector T-cell infiltration, increased effector T-cell

164 This hinders effector T-cell infiltration, proliferation and immune r

165 of the tumor microenvironment, dominated by effector T cell influx.

166 athways govern the differentiation of CD8(+) effector T cells into memory or exhausted T cells during

167 ital imaging indicated failed trafficking of effector T cells into tumors.

168 aerobic glycolytic preference in NLRX1(-/-) effector T cells is combined with a decreased sensitivit

169 ver, accumulation of donor CD4(+) and CD8(+) effector T cells is increased in CD70(-/-) versus wild-t

170 ression of these factors in Treg cells-as in effector T cells-is indicative of heterogeneity of funct

171 as the differentiation and function of other effector T cell lineages.

172 Abnormal epigenetic patterns correlate with effector T cell malfunction in tumours(1-4), but the cau

173 with BNP+RT results in activation of DCs and effector T cells, marked tumor regression, and tumor-spe

174 tudy was to determine whether Tregs suppress effector T cell-mediated and inflammatory cytokine-induc

175 uperior capacity in protecting CEnCs against effector T cell-mediated and interferon-gamma and tumor

176 -deficient Treg cells efficiently suppressed effector T cell-mediated graft-versus-host disease after

177 ation of immune cells, increased central and effector T cell memory, and a significant reduction of p

178 Effector T cell migration through tissues can enable con

179 inhibit generation of early memory precursor effector T cells (MPEC).

180 utcomes of mTORC1 inhibition in naive versus effector T cells: mTORC1 inhibition impaired cell cycle

181 in T cell immune responsiveness or T reg and effector T cell numbers.

182 ic immune activation, along with the altered effector T cell phenotypes and dysregulated T cell homeo

183 s T cell exhaustion state towards memory and effector T cell phenotypes.

184 e ectopic expression of IL-27p28 reduced the effector T cell population and had a major inhibitory ef

185 differentiation, and modulation of specific effector T cell populations generated in the immediate w

186 requencies of IFN-gamma and IL-17A-producing effector T cell populations in female SjS(S) mice compar

187 al serum IgE, Th2 cytokine levels and CD4(+) effector T cell populations than OVA-sensitized WT mice.

188 memory T cell, and terminally differentiated effector T cell populations to the CD3 and CD28-activate

189 ound that miR-155 promotes the activation of effector T cell populations, including T follicular help

190 s experienced increased disease activity and effector T cell populations, whereas no differences were

191 e exhibit increased frequencies of activated/effector T cells producing proinflammatory cytokines, an

192 Memory T cells sustain effector T-cell production while self-renewing in reacti

193 itumor immunity via epigenetic activation of effector T cell programs.

194 version of the same CD25 Ab permitted CD8(+) effector T cell proliferation before progressing to more

195 dy provides a comprehensive map of naive and effector T cell proteomes, and a resource for exploring

196 elevates Tregs to maintain a favorable Treg/effector T cell ratio that limits diabetes by expansion

197 he tumor myeloid compartment are crucial for effector T cell recruitment to the tumor microenvironmen

198 moral Batf3 dendritic cells are critical for effector T cell recruitment.

199 CTLA4 expression on regulatory or effector T cells reduces T cell activation.

200 ogrammed expression of alpha(V)beta(3) tunes effector T cell reliance on environmental cues for optim

201 Expansion of the peanut-specific effector T-cell repertoire is correlated with clinical s

202 hift upon activation, it remains unclear how effector T cells respond to changes in nutrient availabi

203 By contrast, effector T cells responded to glutamine antagonism by ma

204 -1BB treatment preferentially drives CD73(-) effector T cell response for tumor inhibition.

205 i leads to a Th1-polarized parasite-specific effector T cell response in the brain.

206 Although the effector T-cell response in patients with celiac disease

207 nes and chemokines involved in generation of effector T cell responses and migration of inflammatory

208 While early effector T cell responses are required for limiting para

209 H. pylori loads in the stomach by modulating effector T cell responses at the gastric mucosa.

210 Effector T cell responses directed toward cancer neoanti

211 y cells, and dysregulated NK cell and CD4(+) effector T cell responses in infected Rel(C307X) animals

212 re able to induce antigen-specific cytotoxic effector T cell responses that led to in vitro and in vi

213 Similar enhancement of CD8(+) effector T cell responses was observed in MHC-mismatched

214 to better understand many critical phases of effector T cell responses, from activation in the draini

215 maturation and the subsequent development of effector T cell responses.

216 nal characteristics of tolDCs and subsequent effector T cell responses.

217 rom tumor-bearing mice were able to suppress effector T cell responses.

218 mmation by promoting rather than terminating effector T cell responses.

219 CD8alphaalpha T(unc), capable of controlling effector T cell responses.

220 ong the most effective agents in controlling effector T-cell responses in humans.

221 e TB-specific T cells, primarily central and effector T-cell responses in the CD4 compartment and ter

222 disease type 1 diabetes is characterized by effector T-cell responses to pancreatic beta-cell-derive

223 ns, individuals with Down syndrome can mount effector T-cell responses with similar phenotype and fun

224 r programmed cell death ligand 1 can enhance effector T-cell responses.

225 ses were characterized by poor LASV-specific effector T-cell responses.

226 to Lassa virus and poor Lassa virus-specific effector T-cell responses.

227 red by re-engagement of the TCR on a cycling effector T cell, resulting in apoptosis.

228 Effector T cells showed cell-intrinsic responses depende

229 IL-10 from effector T cells signals to CD11c(+) myeloid cells to su

230 ic activity or glucose availability rendered effector T cells significantly less sensitive to RICD.

231 Notably, distinct traits in CD4(+) effector T cell subsets emerged when we focused on a sub

232 Early involvement of effector T cell subsets thus points to a key role of T c

233 ver, intensive expansion of highly cytotoxic effector T cell subsets, such as CD4(+) effector-GNLY (g

234 ells (Tregs) uptake FA at a higher rate than effector T cell subsets, supporting the role of FA metab

235 Here, we show that, among effector T cell subsets, Th17 and Treg cells selectively

236 constitute the entire spectrum of memory and effector T cell subsets.

237 Cs promote the generation of proinflammatory effector T cell subsets.

238 all the phenotypic characteristics of memory-effector T cells such that with acute inactivation of th

239 glucose during anorexia of infection rescued effector T cells, suggesting that this sugar is a limiti

240 integrates Treg cell activity and increased effector T cell survival into an efficient CD4(+) T cell

241 cells demonstrated maturation from an acute effector T cell (T(AEFF)) to an effector memory T cell (

242 unotherapy, owing to its capacity to promote effector T cell (T(eff)) functions(14,15) and hamper reg

243 ppressing the effector functions of multiple effector T cell (T(eff)) lineages.

244 cells into functionally distinct subsets of effector T cells (T helper 1 (TH1), TH2, and TH17) defin

245 pressed the activity of primary human CD8(+) effector T cells (T(eff) cells).

246 ) and increasing the population of activated effector T cells (T(eff)) in the TME can potentiate anti

247 Like effector T cells, T(regs) can specialize in T(H)1-domina

248 treatment site and modulate cancer cells as effector T cell targets.

249 n autoimmune disease that is associated with effector T cell (Teff) destruction of insulin-producing

250 FAS inhibition during priming increased effector T cell (Teff) proliferation and strongly decrea

251 reasing donor graft regulatory T cell (Treg):effector T cell (Teff) ratios can substantially reduce G

252 zed the translatome of virus-specific CD8(+) effector T cells (Teff cells) during acute infection of

253 ction in central nervous system-infiltrating effector T cells (Teff cells).

254 interferon-gamma production by CD4(+)CD25(-) effector T cells (Teff).

255 feration of Foxp3(+) Tregs, but not Foxp3(-) effector T-cells (Teff), when CD4(+) T-cells are co-cult

256 imulation which also causes proliferation of effector T-cells (Teff).

257 g idelalisib compared with CD4(+) and CD8(+) effector T cells (Teffs) as evident from effects on anti

258 rylation (OXPHOS) for energy production, and effector T cells (Teffs) rely on glycolysis for prolifer

259 requencies of interferon gamma (IFNgamma)(+) effector T cells (Teffs), as well as allosensitization i

260 pand regulatory T cells (Tregs) and suppress effector T cells (Teffs).

261 mmune tolerance via control of self-reactive effector T cells (Teffs).

262 etabolic plasticity between cancer cells and effector T cells that can be exploited as a "metabolic c

263 ection, activated naive T cells give rise to effector T cells that clear the pathogen and memory T ce

264 However, the characteristics of the fetal effector T cells that contribute to this process are lar

265 asculitic lesions contain a diverse array of effector T cells that persist despite corticosteroid the

266 T helper (Th) cells are CD4(+) effector T cells that play a critical role in immunity b

267 ion of regulatory T cells and contraction of effector T cells, thereby favoring viral persistence.

268 ce of tumor cells binds its receptor PD-1 on effector T cells, thereby suppressing their activity.

269 specific Tregs and reducing pro-inflammatory effector T cells, these microparticles inhibited destruc

270 ory CD8 T cells are derived from a subset of effector T cells through a process of dedifferentiation.

271 nes downregulated the response of autologous effector T cells to IFX.

272 iciency impairs the ability of self-reactive effector T cells to induce autoimmune disease.

273 uld be reprogrammed toward a higher ratio of effector T cells to regulatory CD4(+) T cells.

274 in Th1 cells and a new mechanism to recruit effector T cells to sites of inflammation.

275 checkpoint signaling, and the relocation of effector T cells to the center of the granulomata.

276 l effector FMNL1 is selectively required for effector T cell trafficking to inflamed tissues, without

277 determinants for T cell antitumor immunity, effector T cell trafficking to the tumor site, and respo

278 abilize Treg cellular identity by repressing effector T cell transcriptional programs.

279 BL-8040 increased CD8(+) effector T cell tumor infiltration, decreased myeloid-de

280 During inflammation, both neutrophils and effector T cells use selectins to roll and integrins to

281 get, IL-10 and IL-35 differentially affected effector T cell versus memory T cell fates, respectively

282 lance between the generation of inflammatory effector T cells versus follicular helper T (T(FH)) cell

283 with Ag, drives differentiation in favor of effector T cells via the activation of mTOR pathway.

284 1 signaling; (2) PD-L1(+) T cells restrained effector T cells via the canonical PD-L1-PD-1 axis and w

285 The frequency and function of fetal-specific effector T cells was assessed in the cord blood of infan

286 resence of TGF-beta, whereas IL-17-producing effector T cells were additionally exposed to IL-6.

287 notype and functionality of antigen-specific effector T cells were analyzed with flow cytometry after

288 Conventional effector T cells were collected from draining lymph node

289 , exhaustion, and apoptosis in the activated effector T cells were inevitable.

290 GUCY2C-specific CD4(+) effector T cells were isolated from immunized, nontolera

291 oneutralization (MN) antibodies and CD4, CD8 effector T cells) were measured at baseline Day (D)0 and

292 o, APECs activated specifically CMV-reactive effector T cells whereas a bispecific T-cell engager act

293 Importantly, SCFAs can induce CD4(+) effector T cells, which are highly inflammatory when tra

294 s require the generation of antigen-specific effector T cells, which home to cutaneous sites of injur

295 CD8 effector T cells with a CD127(hi) KLRG1(-) phenotype are

296 opulation of circulating and tissue-resident effector T cells with immune-regulatory properties.

297 ing into T(SCM) that acts as a reservoir for effector T cells with potent therapeutic characteristics

298 S, functional assays show that CD8+ and CD4+ effector T cells with T21 are resistant to Treg-mediated

299 Solid tumours are infiltrated by effector T cells with the potential to control or reject

300 ecular mechanisms that regulate migration of effector T cells within the interstitial space of inflam